Aplastic anemia in a patient with advanced lung adenocarcinoma during first line osimertinib: A case report and literature review.
Sign Up to like & getrecommendations! Published in 2020 at "Lung cancer"
DOI: 10.1016/j.lungcan.2020.02.019
Abstract: OBJECTIVES Osimertinib is a third-generation, irreversible tyrosine kinase inhibitor of the epidermal growth factor receptor (EGFR-TKI) showing longer progression free survival and overall survival than other EGFR-TKI with an improvement in tolerability. MATERIALS AND METHODS… read more here.
Keywords: lung adenocarcinoma; aplastic anemia; advanced lung; first line ... See more keywords
Complete response to first-line osimertinib monotherapy in a complex epidermal growth factor receptor mutant (L833V/H835L) lung adenocarcinoma patient: a case report.
Sign Up to like & getrecommendations! Published in 2023 at "Anti-cancer drugs"
DOI: 10.1097/cad.0000000000001523
Abstract: Although uncommon epidermal growth factor receptor (EGFR) mutations account for 10-15% EGFR mutant non-small cell lung cancer (NSCLC) patients, clinical evidence for uncommon EGFR mutations, such as complex mutations remain limited. In this study, we… read more here.
Keywords: first line; lung; osimertinib monotherapy; l833v h835l ... See more keywords
Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer
Sign Up to like & getrecommendations! Published in 2020 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-19-3563
Abstract: Purpose: Patterns of resistance to first-line osimertinib are not well-established and have primarily been evaluated using plasma assays, which cannot detect histologic transformation and have differential sensitivity for copy number changes and chromosomal rearrangements. Experimental… read more here.
Keywords: resistance; line; first line; transformation ... See more keywords